MX385498B - Bloqueadores del canal de sodio, metodo de preparacion de los mismos y uso de los mismos. - Google Patents
Bloqueadores del canal de sodio, metodo de preparacion de los mismos y uso de los mismos.Info
- Publication number
- MX385498B MX385498B MX2018009770A MX2018009770A MX385498B MX 385498 B MX385498 B MX 385498B MX 2018009770 A MX2018009770 A MX 2018009770A MX 2018009770 A MX2018009770 A MX 2018009770A MX 385498 B MX385498 B MX 385498B
- Authority
- MX
- Mexico
- Prior art keywords
- pain
- preparation
- same
- neuropathic
- sodium channel
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000003195 sodium channel blocking agent Substances 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000019865 paroxysmal extreme pain disease Diseases 0.000 abstract 2
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 206010003591 Ataxia Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010061533 Myotonia Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 201000011384 erythromelalgia Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un compuesto que tiene un efecto de bloqueo contra los canales del ion sodio, particularmente Nav1.7, un método de preparación del mismo y el uso del mismo. Un compuesto representado por la fórmula 1 de acuerdo con la invención, o una sal farmacéuticamente aceptable, hidrato, solvato o isómero del mismo, se puede usar eficientemente para la prevención o tratamiento del dolor, por ejemplo, dolor agudo, dolor crónico, dolor neuropático, dolor postquirúrgico, migraña, artralgia, neuropatía, lesión de nervio, neuropatía diabética, enfermedad neuropática, epilepsia, arritmia, miotonía, ataxia, esclerosis múltiple, síndrome de intestino irritable, incontinencia urinaria, dolor visceral, depresión, eritromelalgia, o trastorno de dolor extremo paroxístico (PEPD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120114414 | 2012-10-15 | ||
| PCT/KR2013/009206 WO2014061970A1 (en) | 2012-10-15 | 2013-10-15 | Sodium channel blockers, preparation method thereof and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX385498B true MX385498B (es) | 2025-03-18 |
Family
ID=50488472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009770A MX385498B (es) | 2012-10-15 | 2013-10-15 | Bloqueadores del canal de sodio, metodo de preparacion de los mismos y uso de los mismos. |
| MX2015004765A MX374131B (es) | 2012-10-15 | 2013-10-15 | Bloqueadores del canal de sodio, método de preparación de los mismos y uso de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004765A MX374131B (es) | 2012-10-15 | 2013-10-15 | Bloqueadores del canal de sodio, método de preparación de los mismos y uso de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9376429B2 (es) |
| EP (2) | EP2906558B1 (es) |
| JP (1) | JP6251275B2 (es) |
| KR (1) | KR102038607B1 (es) |
| CN (1) | CN104718205B (es) |
| AU (1) | AU2013332648B2 (es) |
| BR (1) | BR112015008508B1 (es) |
| CA (1) | CA2887845C (es) |
| ES (2) | ES2798138T3 (es) |
| IL (1) | IL238296B (es) |
| MX (2) | MX385498B (es) |
| MY (1) | MY177422A (es) |
| RU (1) | RU2645711C2 (es) |
| WO (1) | WO2014061970A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417497D0 (en) * | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| HRP20201695T1 (hr) * | 2015-11-13 | 2020-12-25 | Daewoong Pharmaceutical Co., Ltd. | Blokatori natrijevih kanala |
| EP3390374B1 (en) | 2015-12-18 | 2020-08-26 | Merck Sharp & Dohme Corp. | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| KR20180086259A (ko) | 2016-02-03 | 2018-07-30 | 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 | 헤테로 고리로 치환된 n-설포닐벤즈아미드 유도체, 이의 제조 방법과 약학적 용도 |
| HRP20250505T1 (hr) | 2016-05-20 | 2025-06-20 | Xenon Pharmaceuticals Inc. | Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva |
| ES2967410T3 (es) * | 2016-12-09 | 2024-04-30 | Xenon Pharmaceuticals Inc | Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos |
| CN112262142B (zh) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
| CN111920796A (zh) * | 2020-08-28 | 2020-11-13 | 南京医科大学 | 化合物在制备治疗癫痫药物中的应用 |
| CN119013013A (zh) * | 2021-12-23 | 2024-11-22 | 维拉洛斯治疗公司 | 用于治疗12-脂加氧酶(12-lox)介导的疾病的组合物和使用方法 |
| EP4655291A2 (en) * | 2023-01-26 | 2025-12-03 | Merck Sharp & Dohme LLC | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2240017T3 (es) | 1999-09-30 | 2005-10-16 | Pfizer Products Inc. | Derivados de 6-azauracilo como ligandos de receptores tiroideos. |
| EP1673357A2 (en) | 2003-08-08 | 2006-06-28 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| ATE386715T1 (de) | 2003-11-25 | 2008-03-15 | Lilly Co Eli | Modulatoren des peroxisomproliferatoraktivierten rezeptors |
| JP2008540443A (ja) | 2005-05-04 | 2008-11-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン |
| MX2007015726A (es) | 2005-06-09 | 2008-03-04 | Vertex Pharma | Derivados de indano como moduladores de canales ionicos. |
| EP1995241B1 (en) | 2007-03-23 | 2010-03-17 | ICAgen, Inc. | Inhibitors of ion channels |
| US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
| JP5304785B2 (ja) * | 2008-06-23 | 2013-10-02 | アステラス製薬株式会社 | スルホンアミド化合物又はその塩 |
| PE20120008A1 (es) * | 2009-01-12 | 2012-01-24 | Icagen Inc | Derivados de fenoxi bencenosulfonamida |
| JP5872552B2 (ja) * | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| ES2526675T3 (es) * | 2010-07-09 | 2015-01-14 | Pfizer Limited | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje |
| CA2804593C (en) * | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
-
2013
- 2013-10-15 ES ES18198388T patent/ES2798138T3/es active Active
- 2013-10-15 MX MX2018009770A patent/MX385498B/es unknown
- 2013-10-15 EP EP13846541.4A patent/EP2906558B1/en active Active
- 2013-10-15 CN CN201380053790.3A patent/CN104718205B/zh active Active
- 2013-10-15 BR BR112015008508-3A patent/BR112015008508B1/pt active IP Right Grant
- 2013-10-15 MY MYPI2015000978A patent/MY177422A/en unknown
- 2013-10-15 AU AU2013332648A patent/AU2013332648B2/en active Active
- 2013-10-15 EP EP18198388.3A patent/EP3444249B1/en active Active
- 2013-10-15 US US14/435,473 patent/US9376429B2/en active Active
- 2013-10-15 JP JP2015536720A patent/JP6251275B2/ja active Active
- 2013-10-15 MX MX2015004765A patent/MX374131B/es active IP Right Grant
- 2013-10-15 ES ES13846541T patent/ES2828503T3/es active Active
- 2013-10-15 CA CA2887845A patent/CA2887845C/en active Active
- 2013-10-15 WO PCT/KR2013/009206 patent/WO2014061970A1/en not_active Ceased
- 2013-10-15 RU RU2015113333A patent/RU2645711C2/ru active
- 2013-10-15 KR KR1020130122783A patent/KR102038607B1/ko active Active
-
2015
- 2015-04-14 IL IL238296A patent/IL238296B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015008508B1 (pt) | 2022-06-07 |
| KR20140048059A (ko) | 2014-04-23 |
| AU2013332648A1 (en) | 2015-04-30 |
| CN104718205A (zh) | 2015-06-17 |
| JP6251275B2 (ja) | 2017-12-20 |
| US9376429B2 (en) | 2016-06-28 |
| US20150336944A1 (en) | 2015-11-26 |
| EP2906558A4 (en) | 2016-07-27 |
| RU2645711C2 (ru) | 2018-02-28 |
| CN104718205B (zh) | 2017-12-01 |
| EP3444249B1 (en) | 2020-05-13 |
| AU2013332648B2 (en) | 2017-09-07 |
| BR112015008508A2 (pt) | 2020-01-07 |
| EP3444249A1 (en) | 2019-02-20 |
| MY177422A (en) | 2020-09-15 |
| WO2014061970A1 (en) | 2014-04-24 |
| EP2906558A1 (en) | 2015-08-19 |
| ES2828503T3 (es) | 2021-05-26 |
| IL238296B (en) | 2018-01-31 |
| IL238296A0 (en) | 2015-06-30 |
| KR102038607B1 (ko) | 2019-10-30 |
| MX374131B (es) | 2025-03-05 |
| CA2887845C (en) | 2020-12-15 |
| EP2906558B1 (en) | 2020-09-02 |
| JP2015536917A (ja) | 2015-12-24 |
| MX2015004765A (es) | 2015-08-14 |
| RU2015113333A (ru) | 2016-12-10 |
| ES2798138T3 (es) | 2020-12-09 |
| CA2887845A1 (en) | 2014-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX374131B (es) | Bloqueadores del canal de sodio, método de preparación de los mismos y uso de los mismos. | |
| WO2016129933A3 (en) | Sodium channel blockers | |
| MD20160012A2 (ro) | Formulare de inhibitori SYK | |
| BR112013009365A2 (pt) | uso de um composto da seguinte fórmula (i) ou um sal farmaceuticamente aceitável solvato ou composição do mesmo, composto da formula (i), composição farmaceutica, metodo para o tratamento de uma condição ou desordem em que bloqueadores de canal ttx-s estao envolvidos em um animal, incluindo um humano e processo para preparar uma composiçao farmaceutica. | |
| PH12017501061A1 (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| EA201791955A1 (ru) | ИНГИБИТОРЫ TGF-β | |
| WO2017059385A8 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| WO2015157559A3 (en) | 10',11'-modified saxitoxins useful for the treatment of pain | |
| TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| EA201001848A1 (ru) | Производные пиразина в качестве блокаторов эпителиальных натриевых каналов | |
| MX379264B (es) | Profarmacos de amidas de piridona utiles como moduladores de canales de sodio. | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| EA201001772A1 (ru) | Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей | |
| GT201500334A (es) | Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo | |
| CA3015494C (en) | Novel compositions and therapeutic methods | |
| EA201991253A1 (ru) | Бензодиазолиевые соединения в качестве ингибиторов enac | |
| CL2017002957A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| BR112014018812A8 (pt) | Compostos, processo para preparar os compostos i, composição agroquímica, método para combater fungos nocivos fitopagênicos, uso dos compostos de fórmula i e semente | |
| MX2018001925A (es) | Composiciones que comprenden compuestos triciclicos heterociclicos. | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| PH12016501198A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| NZ742069A (en) | Sodium channel blocker | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| PH12014500006A1 (en) | Voltage-gated sodium channel blockers |